Dudich Elena
Institute of Engineering Immunology, 142380 Lyubuchany, Moscow Region, Chekchov District, Russia.
Curr Opin Mol Ther. 2007 Dec;9(6):603-10.
Merrimack Pharmaceuticals Inc (previously Atlantic Biopharmaceuticals) is developing MM-093 (formerly ABI-001), an injectable formulation of a recombinant human alpha-fetoprotein, for the potential treatment of myasthenia gravis, multiple sclerosis, rheumatoid arthritis, autoimmune uveitis and psoriasis. MM-093 is currently undergoing phase II clinical trials for rheumatoid arthritis, psoriasis and autoimmune uveitis.
美瑞麦克斯制药公司（前身为大西洋生物制药公司）正在研发MM-093（原ABI-001），这是一种重组人甲胎蛋白的注射剂，用于潜在治疗重症肌无力、多发性硬化症、类风湿性关节炎、自身免疫性葡萄膜炎和牛皮癣。MM-093目前正在进行针对类风湿性关节炎、牛皮癣和自身免疫性葡萄膜炎的II期临床试验。
